Baculoviral IAP repeat-containing protein 5 (BIRC5) mRNA, isoform 2B (Survivin-2B mRNA)

Survivin-2B mRNA is a specific splice variant of the BIRC5 gene, which encodes the smallest member of the inhibitor of apoptosis (IAP) protein family. This transcript is generated through the retention of a cryptic exon (exon 2B) from intron 2, leading to a protein product with a modified baculovirus IAP repeat (BIR) domain that often exhibits pro-apoptotic or reduced anti-apoptotic functions compared to the wild-type isoform. While wild-type survivin is a well-known oncogene that promotes cell survival and mitotic progression, Survivin-2B can act as a naturally occurring antagonist by heterodimerizing with the wild-type protein. In clinical oncology, the expression levels of Survivin-2B mRNA and its ratio to the wild-type transcript serve as important biomarkers for tumor aggressiveness and patient prognosis across various malignancies, including neuroblastoma and breast cancer. Therapeutic strategies targeting this mRNA include antisense oligonucleotides (ASOs) like LY2181308 and EZN-3042, which induce RNase H-mediated degradation of the transcript to sensitize cancer cells to apoptosis. Furthermore, the unique sequence of the Survivin-2B isoform has been exploited in the development of peptide-based cancer vaccines designed to trigger a targeted cytotoxic T-cell response against tumor cells.

Other names

BIRC5 variant 2 mRNASurvivin variant 2BBIRC5-2B mRNASurvivin-2B transcriptBaculoviral IAP repeat-containing 5 (BIRC5), transcript variant 2

Antisense-mediated mRNA degradation, RNA interference, Immunotherapy (peptide-based), Transcriptional inhibition